STERIS plc
F:2TG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
STERIS plc
F:2TG
|
IE |
|
C
|
CVS Health Corp
LSE:0HRS
|
US |
|
M
|
Mastercard Inc
BMV:MA
|
US |
|
Bayer AG
MIL:1BAYN
|
DE |
|
R
|
Rockwell Automation Inc
SWB:RWL
|
US |
|
Assicurazioni Generali SpA
OTC:ARZGF
|
IT |
|
Mobvista Inc
HKEX:1860
|
CN |
|
A
|
ACS Actividades de Construccion y Servicios SA
SWB:OCI1
|
ES |
|
Genuine Parts Co
NYSE:GPC
|
US |
|
I
|
Infineon Technologies AG
SWB:IFX
|
DE |
|
P
|
Pioneer Natural Resources Co
DUS:PNK
|
US |
|
Takamatsu Construction Group Co Ltd
OTC:TAKMF
|
JP |
|
B
|
BHP Group Ltd
JSE:BHG
|
AU |
STERIS plc
STERIS plc makes equipment and services that help hospitals, drug makers, and medical device companies keep instruments and products clean, sterile, and safe to use. It sells things like sterilizers, surgical tables, washers, endoscope reprocessing systems, and the chemicals and consumable supplies used with them. It also provides maintenance, repair, and technical support for that equipment. Its main customers are hospitals, outpatient surgery centers, pharmaceutical manufacturers, and medical device makers. STERIS earns money by selling capital equipment up front, then collecting ongoing revenue from replacement parts, service contracts, consumables, and sterilization-related processing services. That mix gives it both one-time sales and repeat business. What makes STERIS different is that it sits in a critical part of the healthcare supply chain. Hospitals and manufacturers rely on its products to meet strict cleanliness and safety standards, so its tools are often deeply embedded in daily operations. That makes the company less about consumer demand and more about essential, regulated workflow inside healthcare and life sciences.
STERIS plc makes equipment and services that help hospitals, drug makers, and medical device companies keep instruments and products clean, sterile, and safe to use. It sells things like sterilizers, surgical tables, washers, endoscope reprocessing systems, and the chemicals and consumable supplies used with them. It also provides maintenance, repair, and technical support for that equipment.
Its main customers are hospitals, outpatient surgery centers, pharmaceutical manufacturers, and medical device makers. STERIS earns money by selling capital equipment up front, then collecting ongoing revenue from replacement parts, service contracts, consumables, and sterilization-related processing services. That mix gives it both one-time sales and repeat business.
What makes STERIS different is that it sits in a critical part of the healthcare supply chain. Hospitals and manufacturers rely on its products to meet strict cleanliness and safety standards, so its tools are often deeply embedded in daily operations. That makes the company less about consumer demand and more about essential, regulated workflow inside healthcare and life sciences.
Strong year: STERIS said fiscal 2026 was a record year, with 9% reported revenue growth, 7% constant currency organic growth, and 10% adjusted EPS growth despite tariff pressure.
Q4 softer: The fourth quarter was described as a lighter finish to a strong year, with 7% reported revenue growth and 5% constant currency organic growth.
Margins and tariffs: Fourth-quarter gross margin was 44% and EBIT margin was 24.2%. Tariffs weighed on results, but management said pricing and favorable tariff changes should help in fiscal 2027.
FY27 outlook: Management guided to 7% to 8% reported revenue growth, $11.10 to $11.30 in EPS, and about 50 bps of EBIT margin expansion at the high end.
Cash return: The board approved a new $1 billion buyback authorization, and management expects to repurchase $200 million to $300 million per year while also raising the dividend.
AST caution: The company was more conservative on AST to start fiscal 2027 because of customer inventory pullbacks and tough first-half comparisons, especially after weather-related disruptions.
